Unknown

Dataset Information

0

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.


ABSTRACT: BACKGROUND:Secukinumab, an anti-interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen. METHODS:A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by subcutaneous secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or matched placebo. Patients in the placebo group were re-randomized to subcutaneous secukinumab at a dose of 300 or 150 mg at week 16. The primary endpoint was the Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response rate at week 16 in the IV-300 mg or IV-150 mg versus placebo. Other endpoints assessed through week 52 included improvements in ASAS40, ASAS 5/6, Bath Ankylosing Spondylitis Disease Activity Index, and ASAS partial remission responses, as well as the change from baseline in high-sensitivity C-reactive protein levels. Statistical analyses followed a predefined hierarchical hypothesis testing strategy to adjust for multiplicity of testing, with non-responder imputation used for binary variables and mixed-model repeated measures for continuous variables. RESULTS:The primary efficacy endpoint was met; the ASAS20 response rate was significantly greater at week 16 in the IV-300 mg (60.5%; P?

SUBMITTER: Pavelka K 

PROVIDER: S-EPMC5741872 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Pavelka Karel K   Kivitz Alan A   Dokoupilova Eva E   Blanco Ricardo R   Maradiaga Marco M   Tahir Hasan H   Pricop Luminita L   Andersson Mats M   Readie Aimee A   Porter Brian B  

Arthritis research & therapy 20171222 1


<h4>Background</h4>Secukinumab, an anti-interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in two phase 3 studies (MEASURE 1 and MEASURE 2). Here, we present 52-week results from the MEASURE 3 study assessing the efficacy and safety of secukinumab 300 and 150 mg subcutaneous maintenance dosing, following an intravenous loading regimen.<h4>Methods</h4>A total of 226 patients were randomized to intravenous secukinumab 10 mg/kg (baseline, weeks 2 and  ...[more]

Similar Datasets

| S-EPMC7725874 | biostudies-literature
| S-EPMC6251842 | biostudies-literature
| S-EPMC9606523 | biostudies-literature
| S-EPMC6744073 | biostudies-literature
| S-EPMC6422944 | biostudies-literature
| S-EPMC6477523 | biostudies-literature
| S-EPMC5132041 | biostudies-literature
| S-EPMC5085310 | biostudies-literature
| S-EPMC7641709 | biostudies-literature
| S-EPMC8572254 | biostudies-literature